New Mycoplasmasynoviae vaccine enters development
UK-headquartered ECO Animal Health is to begin development of a live attenuated Mycoplasmasynoviae vaccine for poultry after signing a second agreement with the University of Georgia.
It follows a similar arrangement between the university and ECO Animal Health for potential vaccines in the field of Mycoplasma gallisepticum.
Researchers at the university have concluded preliminary proof-of-concept for both efficacy and safety for the new vaccine.
Peter Lawrence, Non-Executive Chairman of ECO Animal Health Group plc said, “Mycoplasmasynoviae is a bacterium that affects predominately commercial layers and breeding birds worldwide resulting in a 5%-10% loss in egg production and lower egg quality in affected flocks.”
UGA Professor Naola Ferguson-Noel, a researcher in the Poultry Diagnostic & Research Center said, “We look forward to working with ECO Animal Health to help further develop this Mycoplasma synoviae vaccine into an approved product.”
